Cerliponase Alfa
Basic Information
| Item | Value |
|---|---|
| DrugBank ID | DB13173 |
| Evidence Level | L5 (Computational Prediction) |
| Number of Predicted Indications | 100 |
Predicted Indications (TxGNN)
The following are potential new indications predicted by the TxGNN model. Higher scores indicate higher predicted relevance.
| # | Indication | Source |
|---|---|---|
| 1 | Scheie syndrome | KG + DL |
| 2 | Hurler syndrome | KG + DL |
| 3 | lysosomal storage disease with skeletal involvement | KG + DL |
| 4 | cholesteryl ester storage disease | KG + DL |
| 5 | Gaucher disease | KG + DL |
| 6 | familial encephalopathy with neuroserpin inclusion bodies | KG + DL |
| 7 | Wolman disease with hypolipoproteinemia and acanthocytosis | KG + DL |
| 8 | myoclonic epilepsy, juvenile, susceptibility to | KG + DL |
| 9 | proximal myopathy with extrapyramidal signs | KG + DL |
| 10 | autosomal ichthyosis syndrome with fatal disease course | KG + DL |
| 11 | Wolman disease | KG + DL |
| 12 | adolescent/adult-onset epilepsy syndrome | KG + DL |
| 13 | Tay-Sachs disease | KG + DL |
| 14 | adolescence-adult electroclinical syndrome | KG + DL |
| 15 | growth hormone insensitivity syndrome with immune dysregulation 2, autosomal dominant | KG + DL |
| 16 | adult Krabbe disease | KG + DL |
| 17 | Sanfilippo syndrome | KG + DL |
| 18 | lysosomal acid lipase deficiency | KG + DL |
| 19 | skeletal muscle disease | KG + DL |
| 20 | familial generalized lentiginosis | KG + DL |
| 21 | inclusion myopathy | KG + DL |
| 22 | lysosomal disease with hypertrophic cardiomyopathy | KG + DL |
| 23 | syndromic neurometabolic disease with X-linked intellectual disability | KG + DL |
| 24 | rhabdoid tumor | KG + DL |
| 25 | eyelids malposition disorder | KG + DL |
| 26 | gastrocutaneous syndrome | KG + DL |
| 27 | encephalopathy due to prosaposin deficiency | KG + DL |
| 28 | Krabbe disease | KG + DL |
| 29 | alpha-mannosidosis | KG + DL |
| 30 | Moynahan syndrome | KG + DL |
| 31 | parkinsonism due to ATP13A2 deficiency | KG + DL |
| 32 | neuronal ceroid lipofuscinosis 8 northern epilepsy variant | KG + DL |
| 33 | metachromatic leukodystrophy | KG + DL |
| 34 | osteopathia striata-pigmentary dermopathy-white forelock syndrome | KG + DL |
| 35 | free sialic acid storage disease | KG + DL |
| 36 | congenital multiple café-au-lait macules-increased sister chromatid exchange syndrome | KG + DL |
| 37 | acromelanosis | KG + DL |
| 38 | leukonychia totalis-acanthosis-nigricans-like lesions-abnormal hair syndrome | KG + DL |
| 39 | juvenile Huntington disease | KG + DL |
| 40 | glutaric acidemia type 3 | KG + DL |
| 41 | microcystic/reticular schwannoma | KG + DL |
| 42 | trigeminal schwannoma | KG + DL |
| 43 | schwannoma of twelfth cranial nerve | KG + DL |
| 44 | sympathetic neurilemmoma | KG + DL |
| 45 | peripheral nerve schwannoma | KG + DL |
| 46 | X-linked hereditary sensory and autonomic neuropathy with deafness | KG + DL |
| 47 | recessive X-linked ichthyosis | KG + DL |
| 48 | familial apolipoprotein C-II deficiency | KG + DL |
| 49 | spinocerebellar ataxia 42, early-onset, severe, with neurodevelopmental deficits | KG + DL |
| 50 | Hurler-Scheie syndrome | KG + DL |
(Showing top 50 of 100 predictions)
Disclaimer
These predictions are for research purposes only and do not constitute medical advice. Clinical validation is required before any clinical application.